Organisation: Illumina

IAM’s Market Makers of 2023 

Via Licensing Alliance’s Heath Hoglund takes the top spot in our annual ranking of the patent market’s most innovative and influential deal makers and decision takers

14 March 2024

mRNA firms and other biopharma patentees dominate ‘Innovation Momentum’ rankings

Newly released report throws light on which life sciences companies have the most dynamic IP portfolios

22 February 2024

Natera’s $96 million win is latest big-money decision in contested cell-free DNA testing space

The major victory comes just days after the company was ordered to hand over $57 million in another dispute

02 February 2024

Ravgen notches up another David-v-Goliath victory with $57 million damages award

But the outcome is bitter-sweet for the SME, which has faced many obstacles in its quest to enforce its foundational patents

18 January 2024

Autonomous trucking innovator TuSimple reveals its patent strategy

Follow this roadmap for IP success as a high-growth but pre-revenue tech firm, write TuSimple IP Head Paul Liu and Kent Richardson of Richardson Oliver Law

08 November 2023

Ravgen assertion campaign highlights problems with US patent reforms

The diagnostics innovator has bagged a further $100 million in damages, but the country’s patent system has put unnecessary hurdles in the way, argues representative John Desmarais.

25 May 2023

Busy, busy: US Magistrate Judge Derek Gilliland’s first year saw nearly 400 patent cases

He has already issued nearly 500 rulings since his April 2022 start date in the US District Court for the Western District of Texas, Waco Division

01 May 2023

Ravgen continues winning streak in big-money patent assertion campaign

Illumina settlement and clean sweep at the PTAB have added to earlier $273 million damages award

26 April 2023

300 million reasons why patent owners love litigating in Texas

In what promises to be the largest US jury verdicts this quarter, Texas federal courts ended trials by awarding huge damages to patentees Netlist and Textron

25 April 2023

What BioNTech’s £362 million AI acquisition says about the future of life sciences IP strategies

The convergence of tech and biopharma has major implications for patent professionals

13 January 2023

Unlock unlimited access to all IAM content